POETIG Trial - POnatinib After rEsisTance to Imatinib in GIST

Inclusion Criteria:

* Male or female patients ≥18 years old
* GIST with failure or intolerance to imatinib or failure / intolerance to all three approved TKIs defined as:
* Histologically confirmed metastatic and/or unresectable GIST (harboring a primary KIT or PDGFRA-mutation) after failure or intolerance of imatinib (cohort A and B) or all three approved TKIs (cohort C). If prior TKI treatment was neoadjuvant therapy, then relapse must have occurred during the neoadjuvant therapy in order to consider it failed therapy
* Patients in Cohort A must have evidence of clinical resistance mutations in any other exon or no resistance mutation but evidence of progression by CT or MRI imaging. Patients in Cohort B must have evidence of an activating resistance mutation in KIT exon 13 (by direct sequencing of progressing lesions or by liquid biopsy).
* Measurable disease per modified RECIST 1.1 (Demetri et al., 2013). A lesion in a previously irradiated area is eligible to be considered as measurable disease as long as there is objective evidence of progression of the lesion prior to study enrollment
* Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2
* Adequate hepatic function as defined by the following criteria:
* Total serum bilirubin ≤1.5 x upper limit of normal (ULN), unless due to Gilbert's syndrome
* ALT (Alanine Aminotransferase) ≤2.5×ULN or ≤5.0xULN if liver metastases are present
* AST (Aspartate Aminotransferase) ≤2.5×ULN or ≤5.0xULN if liver metastases are present
* Adequate renal function as defined by the following criterion:
* Serum creatinine \<1.5×ULN
* Adequate pancreatic function as defined by the following criterion:
* Serum lipase and amylase ≤1.5×ULN
* For patients of childbearing potential, a negative pregnancy test must be documented prior to enrollment
* Female and male patients who are fertile must agree to use an effective form of contraception with their sexual partners from signing of the informed consent form for this study through 4 months after the End-of-Treatment Provision of written informed consent
* Willingness and ability to comply with scheduled visits and study procedures
* Fully recovered (≤ Grade 1 or returned to baseline or deemed irreversible) from the acute effects of prior cancer therapy before initiation of the study drug treatment

Exclusion Criteria:

1. Patients lacking primary mutations of KIT or PDGFRA (including Succinate-Dehydrogenase(SDH)-deficient GIST)
2. Major surgery within 28 days prior to initiating therapy
3. History of bleeding disorder
4. History of acute pancreatitis within 1 year of study or history of chronic pancreatitis
5. History of alcohol and /or drug abuse
6. Uncontrolled hypertriglyceridemia (triglycerides \>450 mg/dL)
7. Clinically significant, uncontrolled, or active cardiovascular disease, or other arterial or venous vascular occlusion diseases specifically including, but not restricted to: Myocardial infarction within 6 months prior to enrollment Unstable angina within 6 months prior to enrollment Congestive heart failure within 6 months prior to enrollment, or left ventricular ejection fraction (LVEF) less than lower limit of normal per local institutional standards History of clinically significant (as determined by the treating physician) atrial arrhythmia Any history of ventricular arrhythmia Cerebrovascular accident or transient ischemic attack within 6 months prior to enrollment Any history of peripheral arterial occlusive disease requiring revascularization Venous thromboembolism including deep venous thrombosis or pulmonary embolism within 6 months prior to enrollment
8. Uncontrolled hypertension (diastolic blood pressure \>90 mm Hg; systolic \>140 mm Hg). Patients with hypertension should be under treatment on study entry to effect blood pressure control
9. Taking medications that are known to be associated with Torsades de Pointes (Appendix A)
10. Taking any medications or herbal supplements that are known to be strong inhibitors of CYP3A4 within at least 14 days before the first dose of ponatinib (Appendix B)
11. Ongoing or active infection. This includes but is not limited to the requirement for intravenous antibiotics
12. Known history of human immunodeficiency virus. Testing is not required in the absence of prior documentation or known history
13. Pregnant or breastfeeding
14. Malabsorption syndrome or other gastrointestinal illness that could affect oral absorption of the study drug
15. Individuals with a history of a different malignancy, other than cervical cancer in situ, basal cell or squamous cell carcinoma of the skin, are ineligible, except if they have been disease-free for at least 5 years, and are deemed by the investigator to be at low risk for recurrence of that malignancy OR if the other primary malignancy is neither currently clinically significant nor requiring active intervention.
16. Use of any approved TKIs or investigational agents within 2 weeks or 6 half-lives of the agent, whichever is longer, prior to receiving study drug
17. Any condition or illness that, in the opinion of the investigator, would compromise patient safety or interfere with the evaluation of the drug
18. History of apoplectic insult